Gufic Biosciences to convene 41st AGM on Sep 29, 2025, proposes 10% dividend for FY25
The announcement concerns a routine Annual General Meeting with a standard agenda, including the re-appointment of directors and auditors, and a modest final dividend recommendation. Such events typically do not have a high immediate market impact.
The announcement is procedural, detailing the upcoming 41st Annual General Meeting, book closure dates, and a recommended final dividend. It also includes re-appointment of directors and auditors, which are standard corporate governance items.
Gufic Biosciences Limited announced its 41st Annual General Meeting (AGM) will be held on Monday, September 29, 2025, at 3:30 p.m. (IST) via Video Conferencing (VC) / Other Audio Visual Means (OAVM) to transact ordinary and special businesses.
Key details include: * The Register of Members and Share Transfer Books will be closed from Tuesday, September 23, 2025, to Monday, September 29, 2025 (both days inclusive). * The record date for the AGM and payment of final dividend for the financial year ended March 31, 2025, is Monday, September 22, 2025. * The Board has recommended a final dividend of 10%, which is ₹0.10 per equity share of face value ₹1 each, for the financial year ended March 31, 2025, subject to shareholder approval at the AGM. * Ordinary businesses include: * Adoption of Audited Standalone and Consolidated Financial Statements for FY 2024-25. * Re-appointment of Mr. Jayesh P. Choksi as a director. * Re-appointment of M/s. Mittal Agarwal & Co. as Statutory Auditors for a second term of five consecutive years. * Special businesses include: * Ratification of remuneration of ₹3,00,000 per annum plus taxes for M/s. Poddar & Co. as Cost Auditors for FY 2024-25. * Ratification of remuneration of ₹3,00,000 per annum plus taxes for M/s. Poddar & Co. as Cost Auditors for FY 2025-26. * Appointment of M/s. Manish Ghia and Associates as Secretarial Auditor for five consecutive years, from FY 2025-26 to FY 2029-30. * The remote e-voting period will commence on Friday, September 26, 2025 (9:00 a.m.) and end on Sunday, September 28, 2025 (5:00 p.m.).
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.